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Abstract
Mitochondria are strongly involved in the production of reactive oxygen species, considered as the pathogenic agent of
many diseases and of aging. The mitochondrial theory of aging considers somatic mutations of mitochondrial DNA induced
by oxygen radicals as the primary cause of energy decline; experimentally, complex I appears to be mostly affected and to
become strongly rate limiting for electron transfer. Mitochondrial bioenergetics is also deranged in human platelets upon
aging, as shown by the decreased Pasteur effect (enhancement of lactate production by respiratory chain inhibition). Cells
counteract oxidative stress by antioxidants; among lipophilic antioxidants, coenzyme Q is the only one of endogenous
biosynthesis. Exogenous coenzyme Q, however, protects cells from oxidative stress by conversion into its reduced antioxidant
form by cellular reductases. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The progressive decline of cell functions with age
has been attributed to either a genetic program in-
born in all organisms or to the accumulation of sto-
chastic errors in somatic cells leading to a progressive
loss of cell functions. Among the stochastic theories,
the free radical theory of aging [1] proposed that cells,
continuously exposed to reactive oxygen species
(ROS), are progressively damaged in their most vital
macromolecules. The involvement of mitochondria
both as producers and as targets of ROS has been
the basis for the mitochondrial theory of aging [2] ;
this theory postulates that random mtDNA altera-
tions in somatic cells are responsible for the energetic
decline accompanying senescence. It was proposed
that accumulation of somatic mutations of mtDNA,
induced by exposure to ROS, leads to errors in the
mtDNA-encoded polypeptides; these errors are sto-
chastic and randomly transmitted during mitochon-
drial division and cell division. Such alterations,
which a¡ect exclusively the four mitochondrial com-
plexes involved in energy conservation, would result
in defective electron transfer and oxidative phosphor-
ylation. Respiratory chain defects may further in-
crease ROS production, thus establishing a vicious
circle [3] since any damage to the respiratory chain
may enhance ROS production. It is plausible that an
acute stress would trigger a mechanism inducing cell
death, whereas a milder stress may slowly induce
impairment of cell function, as in aging [4]. The no-
tion of a vicious circle of oxidation and mtDNA
damage is very controversial, and strongly negated
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by some authors [5] ; some aspects related to this
concept can, however, be proved by demonstrating
that ROS production and its e¡ects increase in aging.
The inverse relation of both ROS production and
metabolic rate with normal life span of di¡erent ani-
mal species [6] bears out the idea that mitochondria,
as the sites of oxygen consumption, must be deeply
involved in the aging process. Moreover, it was in-
deed shown that hydrogen peroxide generation in-
creases with age. In isolated rat hepatocytes we
have shown that hydrogen peroxide, but not super-
oxide, production is higher and the e¡ect of an oxi-
dative stress induced by adriamycin is stronger in
cells isolated from old rats than from young animals
[7]. The observed imbalance between superoxide and
hydrogen peroxide may well contribute to enhance
the oxidative stress by producing the hydroxyl radi-
cal by way of the Fenton reaction [8]. The depolari-
zation of the mitochondria induced by adriamycin in
cells from both young and old animals is probably
due to opening of the mitochondrial permeability
transition pore (cf. [9]).
Increased production of ROS in aging is also in-
ferred from the increase of oxidized cellular compo-
nents with age (cf. [4]). Among the damaged mole-
cules, mtDNA is most important for the
mitochondrial theory. The search for point muta-
tions in mtDNA in aging has led to controversial
results [10], but large deletions have been consistently
found in aged individuals [11]. Considering the total
number of deletions, it was suggested that they can
account for such an amount to overcome the thresh-
old required for decreasing the respiratory chain ac-
tivity. Progressive accumulation of somatic mtDNA
rearrangements, formation of mini-circles and pro-
gressive cell death by apoptosis accompany aging
[12]. Recently, high copy mutations at the D-loop
control region for replication and transcription of
mtDNA have been described in ¢broblasts from nor-
mal old but not young individuals [13].
The ¢nding of extensive deletions in aging and the
notion that oxidative stress can induce deletions
[12,14] are no proof per se that oxidative stress is
involved; in fact mtDNA deletions can arise from
altered nuclear-mitochondrial interactions [15].
The cytoplasmic hybrid or ‘cybrid’ transfer tech-
nique is now a standard assay for determining
whether cellular defects associated with mitochon-
drial disease are due to mtDNA mutations. The ob-
servation that oxidative phosphorylation defects in
cultured cells from aged donors could be reversed
by fusion of the enucleated cytoplasmic fragments
from the old donor cells to immortalized recipient
cells [16] suggested that a nuclear mutation might
be responsible for the mitochondrial de¢cit; although
a subsequent study demonstrated formation of respi-
ratory-de¢cient clones having decreased mtDNA
by fusing mitochondria from ¢broblasts of aged
donors to b0 cells [17], the intervention of nuclear
recessive mutations responsible for decreased mito-
chondrial translation in aging was documented by
demonstrating that nuclear hybrids of mtDNA-
less HeLa cells and ¢broblasts from old donors, for-
merly de¢cient in mitochondrial protein synthesis,
resumed normal translation activity [18]. Thus a
unique role of mtDNA in aging has yet to be estab-
lished.
The search for age-dependent changes in mito-
chondrial bioenergetics has produced con£icting re-
sults, reporting either signi¢cant changes or no di¡er-
ences [4]. There may be several reasons for explaining
such con£icting data. First, mtDNA mutations are
expected to accumulate and to lead to damage
mainly in postmitotic cells [19], where oxidative me-
tabolism is very elevated; moreover, in such cells, the
lesions could be conserved, at di¡erence with mitotic
cells where division leads to selection and washing
away of de¢cient cells. Mitochondria, when isolated,
are obtained from tissues containing both di¡erenti-
ated non-dividing cells and relatively non-aging di-
viding cells; thus small changes in one single popu-
lation may become undetectable [4] ; furthermore
energy-de¢cient cells may undergo elimination by ap-
optosis [20]; the continuous cell loss when mitochon-
dria become de¢cient would prevent observing
important energetic changes in the remaining popu-
lation.
The best demonstration of bioenergetic alteration
in mtDNA-encoded proteins has been the histochem-
ical detection of a loss of cytochrome c oxidase ac-
tivity (but not of succinate dehydrogenase) in muscle
mitochondria from old individuals [21] ; the mosaic
distribution of the cytochrome oxidase-de¢cient ¢-
bers agrees with the stochastic distribution of mito-
chondrial damage expected from the mitochondrial
theory [2].
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2. Studies on mitochondria from di¡erent rat tissues
If the energetic impairment derives from a stochas-
tic damage to the mitochondrial genes, then it is
important to select the mitochondrial activity that
is more likely to be a¡ected. Since seven out of the
13 polypeptides encoded by mtDNA belong to com-
plex I, it is expected that this enzyme should be af-
fected most by aging [22]. The membrane part of the
enzyme that carries the binding site of the electron
acceptor, coenzyme Q (CoQ), and of several inhibi-
tors, such as rotenone, is composed of the ND sub-
units which also seem to contribute to the proton-
translocation machinery of complex I [23].
Complex I activity is investigated using low molec-
ular weight quinones [24], which are homologues or
analogues of the natural acceptor, a long isoprenoid
chain ubiquinone. Since problems exist in the correct
evaluation of complex I activity with the arti¢cial
acceptors, we have preferred, when possible, to use
the pool equation [25] to calculate complex I activity
in liver and heart of aged rats; the experimental rates
of NADH-CoQ reductase activity were underesti-
mated, whereas the rates calculated from the pool
equation showed clear decreases of activity in the
aged animals [25].
In non-synaptic mitochondrial particles from rat
brain cortex [26], we found that the aerobic NADH
oxidation is signi¢cantly decreased in old rats, sug-
gesting a complex I defect; in addition to the de-
crease of NADH oxidation rate, we also found a
decrease of its rotenone sensitivity, evidenced as an
increase of the I50, the inhibitor concentration elicit-
ing 50% inhibition of activity. Since rotenone, as well
as most complex I inhibitors, bind hydrophobic ND
subunits [23], this ¢nding would be in line with the
mitochondrial theory. No major changes were found
in synaptic mitochondria from brain cortex, an un-
expected di¡erence whose explanation may be that
they have a lower respiration rate and would there-
fore be less exposed to ROS attack; another explan-
ation could be that only healthy non-damaged mito-
chondria migrate by axonal £ow from the cell body
to the synapse. Similar changes were obtained in liver
mitochondria from 30-month-old rats in comparison
with 4-month-old animals.
The relevance of NADH oxidation to complex I
activity requires that complex I is rate limiting over
the whole respiratory chain, otherwise threshold ef-
fects would be present [27]. The metabolic control
theory [28] determines the control that various steps
in a pathway have over the global £ux of the same
pathway; the £ux control coe⁄cient is de¢ned as the
Fig. 1. Flux control of glutamate plus malate oxidation in rat
liver mitochondria. The ¢gure shows the stepwise inhibition by
rotenone of NADH CoQ reductase (a) and of aerobic state 3
oxidation of glutamate plus malate (b) in mitochondria from
young (A) and old (B) rats. The insets are plots of respiration
rates against inhibition of complex I activity after rotenone ti-
tration. The data points are cumulative of experiments per-
formed in ¢ve rats from each group. NADH-CoQ reductase ac-
tivity was measured with decyl-ubiquinone as acceptor in
mitochondria sonicated in order to make them permeable to
NADH. Absolute values of state 3 respiration, in Wg atoms
oxygen per min per mg protein: young 0.11 þ 0.07, old
0.06 þ 0.02 (di¡erence not signi¢cant) ; NADH-CoQ reductase,
in Wmol per min per mg protein: young 0.15 þ 0.04, old
0.11 þ 0.03 (P6 0.03).
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fractional change in pathway £ux induced by a frac-
tional change in an individual step: values approach-
ing 1 indicate that the step is rate limiting, values
approaching zero indicate that the step is not rate
limiting. Examination of the rotenone inhibition
threshold in NAD-linked respiration (glutamate
plus malate) of intact rat liver mitochondria revealed
a dramatic decrease in the old animals, indicating
that complex I becomes strongly rate limiting with
age (Fig. 1). Accordingly, NADH-CoQ reductase ac-
tivity is signi¢cantly decreased in the old animals (see
legend of Fig. 1).
3. Age-related changes in human platelets
For investigating aging in humans, blood platelets
may represent a unique system, in that they possess
mitochondria and are of easy sampling without in-
volving invasive procedures. The rational use of
platelets as a bio-marker of mitochondrial lesions
[29] rests on the assumption that alterations occur-
ring in senescence and in age-related diseases be
present in all cells, and that platelets may signal gen-
eralized bioenergetic de¢ciencies.
It is known that platelets rely on glycolysis as well
as mitochondrial oxidative phosphorylation for their
energy supply [30]: the main function of platelets is
their energy-dependent aggregation process, a part of
the mechanism of blood clotting, physiologically elic-
ited via exocytosis of their secretory granules.
An alteration of complex I activity in platelet mi-
tochondria in aged individuals is indicated by the
increase of I50 of rotenone inhibition (corrected for
complex I content) [31], similar to that detected in rat
brain cortex mitochondria [26] and in platelet mito-
chondria of patients a¡ected by Leber’s hereditary
optic neuropathy, a maternally inherited mitochon-
drial disease with mtDNA mutations of genes encod-
ing hydrophobic ND subunits of complex I [32].
Cross-titrations with di¡erent inhibitors reveal a
rather extended rotenone-binding area [23]: the
changed rotenone sensitivity concerns three di¡erent
forms of Leber’s disease, implicating subunits ND1,
ND45, and ND6 [32,33]. Since, as already men-
tioned, rotenone binds the hydrophobic sector of
the enzyme that is involved in proton translocation,
the altered inhibitor sensitivity may represent an in-
dication of altered energy conservation. A quantita-
tive determination of glycolytic and mitochondrial
ATP can be provided by the Pasteur e¡ect [30] : a
decreased mitochondrial function stimulates glycoly-
sis in order to maintain a constant ATP synthesis,
and meanwhile pyruvate is reduced to lactate to re-
generate oxidized pyridine nucleotides. Since, in the
absence of mitochondrial function, the stoichiometric
ratio for glucose breakdown in the glycolytic path-
way is two ATP and two lactate molecules per glu-
cose, it follows that the lactate production stimulated
by inhibition of respiration is equivalent to the cor-
respondingly inhibited production of ATP by mito-
chondria.
Lactate production by washed platelets is strongly
enhanced by antimycin A inhibition of mitochondrial
respiration; the v-lactate production in the presence
and absence of antimycin A represents the amount of
ATP produced via oxidative phosphorylation in
physiological conditions, whereas the basal lactate
production represents glycolytic ATP [30]. Both the
v-lactate and the ratio of oxidative ATP over glyco-
lytic ATP are decreased in aged individuals, although
the latter values display much larger variability (Ta-
ble 1). The decreased extent of stimulated activity in
the aged, also evident from Table 1, would argue for
a decreased capacity of the glycolytic system; this,
however, can be excluded by the ¢nding that platelet
aggregation in the presence of antimycin (and there-
fore only supported by glycolysis) is not di¡erent in
young and old individuals (not shown). A possible
reason would be in a diminished ATP utilization in
the old.
The site of the mitochondrial bioenergetic lesion
observed in platelets is probably respiratory complex
I, as shown by the decreased rotenone sensitivity of
this enzyme in the aged [31]. We found that the
‘common’ deletion of mtDNA, detected in all post-
mitotic tissues investigated so far [11], is not present
in platelets [34]; the mitochondrial theory expects
mtDNA to be a¡ected in postmitotic tissues but
not in mitotic or short-lived cells [19], although
highly glycolytic cells may be thought to accumulate
mitochondrial damage without being negatively se-
lected. The recent observations of a high incidence
of age-linked mutations in the D-loop region of di-
viding ¢broblasts [13] re-launches the mitochondrial
theory; however, we cannot exclude other causes of
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the bioenergetic defects occurring in senescence; a
decreased stability in complex I protein structure,
leading to decreased rotenone sensitivity and to de-
creased energy conservation, could be alternatively
due to direct damage of the enzymatic proteins or
of the lipid environment of the enzyme [4]. To this
respect, the reported decrease of cardiolipin content
in the aged was accompanied by decreased cyto-
chrome oxidase activity [35].
4. Oxidative stress and antioxidant role of
coenzyme Q
Cells contain enzymatic and non-enzymatic sys-
tems capable to convert ROS into less toxic or
non-toxic species. Among antioxidants, a special po-
sition is held by coenzyme Q, the only lipid-soluble
antioxidant which is normally synthesized by the or-
ganism [36]. The biosynthesis of CoQ is particularly
complex: the benzoquinone ring is synthesized from
the essential amino acid phenylalanine up to 4-hy-
droxybenzoate, whereas the isoprenoid chain is
formed by a pathway common to that of cholesterol
and dolichol biosynthesis [37]. CoQ biosynthesis re-
quires the dietary intake of several vitamin cofactors;
it is therefore conceivable that one or more such
factors may become limiting [36], thus slowing
down ubiquinone biosynthesis and inducing a de¢-
ciency state.
Besides its bioenergetic role, as a component of the
mitochondrial respiratory chain, CoQ is also a com-
ponent of extramitochondrial redox chains, whose
function, among others, would be to remove excess
reducing power formed by glycolysis when mitochon-
drial respiration is decreased [38]. The role of CoQ in
relation with ROS is intriguing: in spite of the CoQ
intermediates in the function of complexes I and III
being considered as the source of one-electron oxy-
gen reduction [4], ubiquinone in its reduced form is a
powerful antioxidant. As an antioxidant, the reduced
form of CoQ is exploited either directly upon super-
oxide or indirectly on lipid radicals [39]; ubiquinol
can also act together with vitamin E (K-tocopherol)
by regenerating the active form from the tocopher-
oxyl radical [40]. The antioxidant action of ubiquinol
yields the ubisemiquinone radical; this species is con-
verted back to its antioxidant form by re-reduction,
which occurs through the electron transfer chain in
mitochondria, and is operated by various quinone
reductases present in di¡erent cell fractions [41,42],
including the plasma membrane [43]. Ubiquinone
may be transformed from a safe electron carrier to
a superoxide generator when the ubisemiquinone
anion, arising from one-electron oxidation of ubiqui-
nol, becomes accessible to protons [44] ; such a con-
dition may originate from changes in membrane
structure.
Studies in perfused rat liver [45] and in isolated rat
hepatocytes [41] clearly showed the antioxidant e¡ect
of exogenous added CoQ10. The anticancer quinone
glycoside, adriamycin, induces an oxidative stress by
enhancing ROS production in mitochondria and en-
doplasmic reticulum. In hepatocytes, adriamycin en-
hances ROS production; concomitantly endogenous
CoQ is re-oxidized and the mitochondrial membrane
potential falls. Incubation of the cells with exogenous
CoQ10 prevents ROS formation and protects both
reduced CoQ and the v8mit (Fig. 2). The cytosolic
enzyme DT-diaphorase seems to be responsible for
reduction of both endogenous and exogenous CoQ,
as shown by the e¡ect of dicoumarol, an inhibitor of
DT-diaphorase, preventing the protective action of
exogenous CoQ addition [41]. We have found an
increase of the plasma membrane oxidoreductase sys-
tem, including an increase of DT-diaphorase (its di-
coumarol-sensitive portion) in insulin-dependent dia-
betic patients whose mitochondrial function was also
Table 1
Lactate production in platelets from young and aged individuals
Control (A) +Antimycin A (B) v-Lactate (C) C/A
Young 0.45 þ 0.28 4.18 þ 1.04 3.73 þ 1.09 26.5 þ 57.9
Old 0.85 þ 0.78 3.47 þ 0.85 2.62 þ 0.89 5.4 þ 4.9
P 0.021 0.009 0.0002 0.09
Data from 26 individuals from each group. Values are Wmol lactate produced per minute per 1011 cells þ S.D.
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found to be a¡ected [46]; such an increase may be
related, besides to the necessity of releasing the ex-
cess of cytosolic reducing power [20], to a higher
requirement for the reduced antioxidant form of
CoQ, due to the oxidative stress occurring in diabe-
tes.
If aging is the result of prolonged oxidative stress,
an adequate antioxidant supply might contrast the
process. The content of vitamin antioxidants depends
on dietary intake, and may be subjected to decreases
due to de¢cient intestinal absorption defects and bad
dietary habits of the aged. CoQ, being synthesized, is
a special case. Some studies have shown a CoQ de-
crease with age (discussed in [25]); however, this is
not true for brain, where high levels are maintained
throughout aging [47,48] in accordance with the
steady level of nonaprenyl-4-hydroxybenzoate trans-
ferase [48]. Nevertheless, even if the levels of CoQ
and other antioxidants do not dramatically fall
with aging, we must consider that the antioxidant
defenses should actually strongly increase to cope
with the enhanced oxidative stress, as was indeed
found under conditions of surgical stress [49].
Senescence is associated to increased incidence of
degenerative diseases, such as Parkinson’s and Alz-
heimer’s diseases and age-linked macular degenera-
tion; these diseases often have a strong genetic com-
ponent, which is, however, associated to exogenous
factors, among which oxidative stress and mitochon-
drial involvement may be major triggering factors
(cf. [50]). A decrease of CoQ10 and of antioxidant
defenses in plasma was found in our laboratory in
patients a¡ected by age-related macular degeneration
of the retina [51].
Fig. 2. Protection by exogenous CoQ10 of isolated rat hepatocytes from oxidative stress induced by 50 WM adriamycin. Experimental
conditions were as in [40]. The mitochondrial membrane potential v8mit was measured by £ow cytometry using rhodamine 123 as
probe; data are expressed in £uorescence arbitrary units. Hydrogen peroxide was assayed by £ow cytometry and dichloro£uorescein
diacetate as probe; data are expressed as pmol/106 cells using a calibration curve. Reduced and oxidized CoQ homologues were as-
sayed by HPLC. Total CoQ9 concentration in controls was 727.6 pmol/106 cells and did not vary after adriamycin and CoQ10 addi-
tion; total CoQ10 was 125.2 pmol/106 cells in controls and did not vary after adriamycin addition; after addition of exogenous
CoQ10, its content rose to 1154.0 pmol/106 cells.
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The proposal of an antioxidant therapy, as an at-
tempt to reduce or retard the damaging e¡ect of
ROS in aging and age-related degenerative diseases,
is strongly supported by the excellent results ob-
tained in Alzheimer disease and Huntington disease
[52]. The use of CoQ as a dietary supplement re-
quires its distribution to de¢cient tissues. Dietary
CoQ is quickly taken up into blood, where it is
mainly transported by LDL [53], and is rapidly in-
corporated in liver and reticulo-endothelial cells. The
uptake of CoQ10 by other tissues has not been shown
in nutritional experiments in the rat [54], although
there are indirect observations suggesting its incorpo-
ration in tissues when the endogenous levels are low-
ered [55]. In spite of the lack of uptake of dietary
CoQ10 by rat heart mitochondria, the exogenous qui-
none was found in our studies to strongly protect
mitochondria from oxidative changes [56].
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